SILBIOTECH, INC.

Medtech · Defunct

Multimarker-based diagnostic test using gene expression to stratify breast cancer risk in patients with precancerous lesions and generate a Cancer Risk Score

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$1.6M
Federal grants
$1.6M
2 awards · 2016–2017
Rank in peer group#19 of 79
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
2 pending · first 2019
Rank in peer group#19 of 79

Capital timeline

20162017FEDERAL ↑EQUITY ↓Cumulative $1.6M$1M$567K
20162017FEDERAL ↑EQUITY ↓Cumulative $1.6M$1M$567K

Latest events

  • Federal grantHealth and Human S · Phase II · Technology to Select Candidates for Prophylactic Treatments to Prevent Sporadic Breast Cancers$567K
  • Federal grantHealth and Human S · Phase II · Technology to Select Candidates for Prophylactic Treatments to Prevent Sporadic Breast Cancers$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 79 peers

Line = median

Medtech · Instrument

  • Federal grants#19 · top 24%
  • Granted patents#19 · top 24%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 3
  • PendingMethods For Determining Breast Cancer RiskUSPTOApplication 16528052
  • GrantedMethods For Determining Breast Cancer RiskUSPTOUS 10,416,164
  • PendingMethods For Determining Breast Cancer RiskUSPTOApplication PCTUS2018017222

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .